Trials / Unknown
UnknownNCT05112159
Study of IPG1094 in Healthy Participants
A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of Orally Administered IPG1094 in Healthy Adult Participants
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- Nanjing Immunophage Biotech Co., Ltd · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
This is a phase 1, first-in-human, randomized, double-blind, placebo-controlled, single dose escalation study to evaluate the safety, tolerability, and PK of single dose orally administered IPG1094 in healthy adult participants.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IPG1094 | The IPG1094 drug product is supplied as oral tablet dosage form, containing two strengths: 50 mg and 100 mg, respectively, which contain IPG1094. |
| DRUG | placebo | Matching placebo tablets to IPG1094 50mg and 100mg |
Timeline
- Start date
- 2021-09-27
- Primary completion
- 2022-05-18
- Completion
- 2022-07-30
- First posted
- 2021-11-08
- Last updated
- 2021-11-08
Locations
1 site across 1 country: Australia
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05112159. Inclusion in this directory is not an endorsement.